Search the Newsreel

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for Replimune Group, Inc. (NASDAQ: REPL) regarding a securities class action lawsuit. Shareholders who purchased REPL shares between October 20, 2025, and April 10, 2026, are encouraged to contact the firm, as the complaint alleges …

Replimune Group stock may move 5.6% on earnings release

Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group Inc. (REPL) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating Replimune Group Inc. (REPL) after the FDA deemed the company's lead trial for its skin cancer drug RP1 "not interpretable," causing a significant drop in stock price. The firm is encouraging shareholders who purchased Replimune securities to …

Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results

Replimune Group (NASDAQ:REPL) reported a Q1 loss of $0.72 per share, missing analyst estimates. Despite the earnings miss and ongoing litigation, the company's shares fell by 1.4% to $14.97, and it expects to launch TUDRIQEV™ (RP1) for advanced melanoma within 60 days following FDA …

REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on

Kirby McInerney LLP has filed a securities fraud class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made misleading statements regarding the Biologics License …

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

SueWallSt is reminding shareholders of Replimune Group, Inc. (REPL) about a lead plaintiff deadline of October 5, 2026, in a securities class action lawsuit. The lawsuit alleges that Replimune made misleading statements regarding the FDA's review of its RP1 resubmission, leading to an 84% …

Replimune Group Stock Short Interest Rises to 57.95%

Replimune Group Inc. (NASDAQ:REPL) saw a significant increase in short interest during July, rising 57.95% to 5.25 million shares. This represents 14.7% of the company's shares outstanding, indicating a growing bearish sentiment among investors. The average daily trading volume suggests it would take approximately …

Repligen Corporation (RGEN) Stock Forecasts

Argus has raised its target price for Repligen Corporation (RGEN) to $173.00. Repligen, a global life sciences company, specializes in developing bioprocessing equipment and supplies for manufacturing biologic drugs. The current stock price for RGEN is $167.49.

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Levi & Korsinsky, LLP has issued a shareholder alert regarding a securities class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL). The lawsuit alleges that Replimune misled investors between October 20, 2025, and April 10, 2026, by claiming its RP1 FDA resubmission was on …

Replimune Group (NASDAQ:REPL) CAO Sells 7,632 Shares

Replimune Group's CAO, Andrew Schwendenman, sold 7,632 shares of the company's stock for approximately $98,987 to cover tax-withholding obligations. Despite this insider sale, Replimune has seen positive analyst sentiment and recently priced a $150 million public offering for its oncology pipeline. However, the company …

Replimune Group (NASDAQ:REPL) Insider Sells 11,447 Shares of Stock

Konstantinos Xynos, an insider at Replimune Group (NASDAQ:REPL), sold 11,447 shares of the company's stock for approximately $148,468 to cover tax obligations. Despite the sale, Replimune's stock has performed strongly, nearing its 52-week high, although the company reported a larger-than-expected quarterly loss. Institutional ownership …

Replimune group CEO Sushil Patel sells $510,252 in stock

Replimune Group CEO Sushil Patel sold 39,341 shares of the company's common stock for $510,252 on August 10, 2026, to cover tax withholding obligations. This sale was not discretionary and was tied to performance-based restricted stock units. The company has recently received FDA accelerated …

What happened at FDA? Replimune approval raises questions

The article discusses the accelerated approval of Replimune Group Inc.'s biologic, RP1, by the FDA for advanced melanoma, following a 10:3 advisory committee vote. This approval comes after a protracted process involving two previous rejections, political pressure, and significant debate among experts about the …

REPL Class Action Reminder - Robbins LLP Reminds Investors

Robbins LLP is reminding investors of a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL). The lawsuit alleges that Replimune misled investors about the efficacy and viability of its lead product candidate RP1, after the FDA rejected its Biologics License Application due to …

Wasatch Advisors LP Buys 346,720 Shares of Repligen Corporation $RGEN

Wasatch Advisors LP has significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) by 27.9%, purchasing an additional 346,720 shares, bringing its total holdings to 1.59 million shares valued at approximately $217 million. This makes Repligen the 19th largest holding for Wasatch Advisors, representing 1.4% …

Assenagon Asset Management S.A. Buys New Shares in Repligen Corporation $RGEN

Assenagon Asset Management S.A. has acquired 70,995 new shares of Repligen Corporation (NASDAQ:RGEN) valued at approximately $9.7 million, making them a 0.13% owner of the biotechnology company. Repligen recently surpassed its quarterly earnings and revenue expectations, reporting $0.54 EPS against a $0.45 consensus, with …

REPL INVESTOR NOTICE: Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) for purchasers of securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false and misleading statements regarding its Biologics License Application …

Baker Bros. Advisors (NASDAQ: REPL) details 11.8% stake and warrant buys

Baker Bros. Advisors and related entities have filed an amended beneficial ownership report for Replimune Group, Inc. common stock, revealing a beneficial ownership of 11,075,336 shares, which represents an 11.8% stake. The report also details Baker Bros.' purchase of all 2,736,340 pre-funded warrants in …

Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz announced that investors who suffered losses with Replimune Group, Inc. (REPL) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that between October 20, 2025, and April 10, 2026, Replimune made false …

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

Pomerantz LLP has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) for alleged securities fraud. The lawsuit comes after the FDA rejected Replimune's Biologics License Application for RP1, citing several deficiencies in its studies, leading to significant drops in the company's …

Replimune Group, Inc. (REPL) stock price, news, quote and history

This Yahoo Finance page provides a comprehensive overview of Replimune Group, Inc. (REPL) stock, including its current price, news headlines, and performance data. The stock is listed on NasdaqGS and shows recent fluctuations based on FDA decisions regarding its drug candidates. News articles detail …

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) for alleged securities fraud. The lawsuit, covering the period from October 20, 2025, to April 10, 2026, claims Replimune made misleading statements by failing to disclose …

Replimune Prices $150 Million Underwritten Offering

(RTTNews) - Replimune Group, Inc. (REPL), a commercial-stage biotechnology company developing oncolytic immunotherapies, announced the pricing of an underwritten offering of 9,701,490 shares of its common stock at $12.06 per share. In addition, the company is issuing pre-funded warrants, equal to the offering price …

Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Brokerages

Repligen Corporation (NASDAQ:RGEN) has received a "Moderate Buy" consensus rating from eighteen brokerages, with an average 12-month price target of $166.43. The company recently surpassed quarterly earnings and revenue expectations, reporting $0.54 EPS and $204.13 million in revenue, an 11.9% year-over-year increase. Despite a …

Repligen Shares Surge 16.2% as Record Revenue Offsets Shrinking Q2 Margins

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false and misleading statements regarding its …

Replimune Group stock hits 52-week high at 13.92 USD

Replimune Group stock has reached a 52-week high of $13.92, driven by a 128% one-year return and recent FDA accelerated approval for its cancer treatment TUDRIQEV. While analysts have upgraded the stock and increased price targets, InvestingPro suggests the shares may be overvalued, and …

Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months

Replimune Group's stock has surged nearly 223% in the past three months, primarily due to the FDA's accelerated approval of its lead oncolytic immunotherapy, RP1 (Tudriqev), for advanced melanoma. This approval, in combination with Bristol Myers' Opdivo, marks a significant commercial milestone for Replimune …

Replimune prices $150M underwritten offering of common stock and pre-funded warrants

Replimune (REPL) has priced an underwritten offering to raise approximately $150.0 million in gross proceeds. The offering includes 9,701,490 shares of common stock and pre-funded warrants for 2,736,340 shares, priced at $12.06 per share. Net proceeds are estimated to be around $140.5 million after …

Repligen Corporation (RGEN) Stock Analysis: A Healthcare Standout with 13.3% Potential Upside

Repligen Corporation (RGEN) is analyzed as a strong player in the healthcare sector, specifically medical instruments and supplies, with a current market cap of $9.25 billion and a potential upside of 13.3% according to analysts. The company shows promising revenue growth, positive analyst sentiment …

Repligen (RGEN) Is Up 16.2% After Revenue Rises But Profitability Compresses In Q2 2026

In July 2026, Repligen Corporation reported second-quarter 2026 results showing revenue of US$204.13 million versus US$182.37 million a year earlier, while net income fell to US$5.01 million from US$14.87 million and diluted EPS from continuing operations decreased to US$0.09 from US$0.26. Over the six-month …

Repligen (RGEN) Could Be 10% Below Fair Value On Mixed Q2 Earnings

Repligen (RGEN) recently reported mixed Q2 2026 earnings, showing higher revenue but lower net income and EPS year-over-year. Despite this, the stock has seen strong recent momentum, with a 90-day return of 41.4% and a 1-year return of 47.09%, positioning it about 10% below …

Replimune in the spotlight: Earnings loom days after FDA approval

Replimune Group Inc. is set to report its fiscal fourth-quarter earnings, marking its first financial update since receiving FDA approval for its melanoma therapy, Tudriqev. Despite the regulatory success, analysts have significantly lowered EPS estimates, though most still rate the stock a "Buy" with …